Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
$0.38
-1.7%
$0.41
$0.30
$10.62
$54.34M23.36 million shs885,552 shs
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
$1.45
+2.1%
$1.43
$1.12
$3.26
$14.75M2.1327,536 shs16,099 shs
ImmuCell Co. stock logo
ICCC
ImmuCell
$6.25
$5.35
$3.34
$6.84
$56.48M0.2321,999 shs13,885 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$1.99
-9.5%
$1.97
$1.14
$12.45
$61.64M1.74366,705 shs198,200 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
-1.75%-0.21%-3.75%-26.20%-90.91%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
+2.11%+1.40%-12.12%-16.18%-35.56%
ImmuCell Co. stock logo
ICCC
ImmuCell
0.00%+1.79%+13.62%+16.82%+42.37%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-9.32%-9.73%+4.45%-25.56%-83.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
3.7813 of 5 stars
3.31.00.04.72.22.50.6
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
2.5721 of 5 stars
3.53.00.00.02.61.70.6
ImmuCell Co. stock logo
ICCC
ImmuCell
0.2217 of 5 stars
0.03.00.00.02.00.00.0
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1.26 of 5 stars
3.52.00.00.01.50.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
2.50
Moderate Buy$6.101,517.61% Upside
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
3.00
Buy$7.00382.76% Upside
ImmuCell Co. stock logo
ICCC
ImmuCell
0.00
N/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
3.00
Buy$16.60734.17% Upside

Current Analyst Ratings Breakdown

Latest COCP, ICCC, SKYE, and APLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/14/2025
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$1.50 ➝ $1.50
3/21/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
3/21/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/28/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
$265K201.47N/AN/A($0.20) per share-1.89
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/A$2.59 per shareN/A
ImmuCell Co. stock logo
ICCC
ImmuCell
$27.30M2.07N/AN/A$3.23 per share1.93
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A($0.17) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
-$119.76M-$0.43N/AN/AN/AN/A-260.75%-76.04%8/6/2025 (Estimated)
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$17.98M-$1.57N/AN/AN/AN/A-94.62%-78.24%8/13/2025 (Estimated)
ImmuCell Co. stock logo
ICCC
ImmuCell
-$5.78M-$0.07N/AN/A-15.99%-15.32%-8.81%8/11/2025 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$37.65M-$0.82N/AN/AN/AN/A-45.78%-37.44%N/A

Latest COCP, ICCC, SKYE, and APLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$0.52-$0.23+$0.29-$0.23N/AN/A
5/14/2025Q1 2025
ImmuCell Co. stock logo
ICCC
ImmuCell
N/A$0.16N/A$0.16N/A$8.07 million
5/8/2025Q1 2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.31-$0.28+$0.03-$0.28N/AN/A
4/14/2025Q4 2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
-$0.18-$0.24-$0.06$0.33$0.61 million$0.00 million
3/27/2025Q4 2024
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$0.55-$0.32+$0.23-$0.32N/AN/A
3/20/2025Q4 2024
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.30-$0.24+$0.06-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
N/AN/AN/AN/AN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/AN/A
ImmuCell Co. stock logo
ICCC
ImmuCell
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
N/A
1.06
1.06
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/A
7.32
7.32
ImmuCell Co. stock logo
ICCC
ImmuCell
0.36
3.11
1.44
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
14.19
14.19

Institutional Ownership

CompanyInstitutional Ownership
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
98.31%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
6.72%
ImmuCell Co. stock logo
ICCC
ImmuCell
13.47%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%

Insider Ownership

CompanyInsider Ownership
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
8.60%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
28.14%
ImmuCell Co. stock logo
ICCC
ImmuCell
6.60%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
30141.58 million106.35 millionOptionable
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
1010.17 million7.57 millionNot Optionable
ImmuCell Co. stock logo
ICCC
ImmuCell
709.04 million8.32 millionNot Optionable
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1130.98 million29.43 millionOptionable

Recent News About These Companies

Leo Miller: Page 6

New MarketBeat Followers Over Time

Media Sentiment Over Time

Applied Therapeutics stock logo

Applied Therapeutics NASDAQ:APLT

$0.38 -0.01 (-1.75%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.38 +0.01 (+2.09%)
As of 05/28/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Cocrystal Pharma stock logo

Cocrystal Pharma NASDAQ:COCP

$1.45 +0.03 (+2.11%)
Closing price 05/28/2025 03:55 PM Eastern
Extended Trading
$1.46 +0.01 (+0.97%)
As of 05/28/2025 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

ImmuCell stock logo

ImmuCell NASDAQ:ICCC

$6.25 0.00 (0.00%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$6.25 0.00 (0.00%)
As of 05/28/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$1.99 -0.21 (-9.55%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$2.01 +0.02 (+0.80%)
As of 05/28/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.